WEBULL
News
EBS
12.16
-0.49%
-0.06
Weekly Report: what happened at EBS last week (1222-1226)?
Weekly Report · 1d ago
Emergent BioSolutions Inc. (NYSE:EBS) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Simply Wall St · 12/23 10:27
Weekly Report: what happened at EBS last week (1215-1219)?
Weekly Report · 12/22 09:55
Institutional investors have a lot riding on Emergent BioSolutions Inc. (NYSE:EBS) with 73% ownership
Simply Wall St · 12/20 12:34
Emergent Biosolutions Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 12/16 11:53
HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $15 Price Target
Benzinga · 12/16 11:43
Emergent BioSolutions Receives Buy Rating Amid Strategic Milestones and Strong Market Position
TipRanks · 12/16 11:26
Weekly Report: what happened at EBS last week (1208-1212)?
Weekly Report · 12/15 10:00
Emergent BioSolutions Gains FDA Approval for Winnipeg Facility
TipRanks · 12/12 14:01
Emergent BioSolutions receives FDA approval for raxibacumab manufacturing
TipRanks · 12/12 13:36
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
Barchart · 12/12 07:30
Director Cashes In on Emergent Biosolutions Stock
TipRanks · 12/10 02:05
Weekly Report: what happened at EBS last week (1201-1205)?
Weekly Report · 12/08 09:59
Weekly Report: what happened at EBS last week (1124-1128)?
Weekly Report · 12/01 09:56
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
Simply Wall St · 11/27 10:14
Weekly Report: what happened at EBS last week (1117-1121)?
Weekly Report · 11/24 09:59
Weekly Report: what happened at EBS last week (1110-1114)?
Weekly Report · 11/17 09:59
Emergent BioSolutions Announces Board Member Retirement
TipRanks · 11/12 21:48
Press Release: Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
Dow Jones · 11/12 21:01
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS), Emergent Biosolutions (EBS) and Ginkgo Bioworks Holdings (DNA)
TipRanks · 11/10 11:30
More
Webull provides a variety of real-time EBS stock news. You can receive the latest news about Emergent Biosolutions Inc through multiple platforms. This information may help you make smarter investment decisions.
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.